Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
Primary Objective: Score out of 44 on a validated test of anatomy and sono-anatomy
Secondary Objective:
Before training
After training and testing
Study population: Resident anaesthetists
Recruitment Target: 102
Methodology:
This is a non-clinical randomised controlled trial of resident anaesthetists undergoing training in regional anaesthesia. Residents will be randomised to one of two groups for each training session day:
Anatomical knowledge will be tested in both groups using an on-line questionnaire developed by the Chief Investigator.
Eligibility criteria: Inclusion criteria:
Exclusion criteria:
Study treatment:
Standard teaching - control Virtual reality teaching - intervention
Full description
STUDY RATIONALE AND RISK/BENEFIT ANALYSIS We propose that in order to develop a sound knowledge of anatomy and sono-antomy, virtual reality could be used as an aid to understanding and interpreting 2-D sono-antomical structures. Trainees will have an enhanced learning experience that reinforces the skills required to perform safe regional anaesthesia.
Hypothesis: We hypothesise that knowledge of regional nerve anatomy among novice anaesthetists using 3D virtual reality is equivalent to standard teaching.
MANAGEMENT OF POTENTIAL STUDY RISKS One potential major weakness is the risk of trainer bias when delivering training. The knowledge test was written by Dr Bellew, and that Dr Bellew and Prof McLeod will be delivering the 'VR training' and 'standard training' arms respectively. The possibility exists for the trainers to bias results by providing test-specific training to one arm, but not the other. To mitigate this risk training packages with specific anatomical areas taught and check lists will be used by an observer to ensure all aspects are taught and/or omitted as per the training package.
Virtual reality is usually regarded as safe to use. There are reports of it causing headache, eyestrain, fatigue, blurred vision and dizziness with prolonged use. These symptoms tend to get better shortly after participants stop using the virtual reality equipment. We will minimise the risk of these symptoms by limiting the use of the virtual reality headset to 2 - 3 x 30-40 minute sessions within an eight-hour period. We will be assessing for these side effects using validated questionnaires. Also, the VR environment will be projected onto a screen for participants if they need to remove the VR equipment.
PRIMARY OBJECTIVE Our primary aim is to study knowledge of anatomy following initial VR teaching compared to standard teaching.
Primary end-point: Score out of 44 on a validated test of anatomy and sono-anatomy
SECONDARY OBJECTIVES
Secondary objectives and end-points:
Before training
Experimental design and methods (Workpackage (WP); Milestone (M); Deliverables (D)) WP 1 Baseline measurements M 1.1 Confirmation of capacity and capability (C&C) at each site M 1.2 Inclusion criteria: anaesthetists (non-pregnant) from London, Nottingham, Tayside, Sunderland.
M 1.3 Measure online participant characteristics and psychometric measures (secondary outcomes as above) using web based Inquisit Lab 5 platform (Millisecond Software, Seattle).
D1 Report results. WP 2 Training and testing M 2.1 Randomisation Participants will be randomised to one of two groups
Training will cover upper and lower limb blocks, truncal and abdominal blocks. The standard session will consist of a lecture followed by learning on a plastic anatomical model. All training to be provided by Dr Bellew and Prof McLeod at all centres M 2.5 Testing Knowledge will be tested four occasions and pseudoanonymised using a random code generator.
INCLUSION CRITERIA Anaesthetists that are in a recognised Royal College of Anaesthetists (RCoA) training program in the Uk, Anaesthetic training grades (Stage 1 - 3).
EXCLUSION CRITERIA
PARTICIPANT RECRUITMENT PROCESS
Participant recruitment at a site will only commence once the study team has ensured that the following approvals/essential documents are in place:
All sites participating in the study will also be asked to provide a copy of the following:
INFORMED CONSENT Consent to enter the study will be sought from each participant only after a full explanation has been given, an information leaflet offered, and time allowed for consideration. Signed participant consent will be obtained. The right of the participant to refuse to participate without giving reasons must be respected. All participants are free to withdraw at any time.
Informed consent will be obtained by the Chief Investigator (CI), Principal Investigator (PI) and/or a nominated deputy as recorded on Sponsor's Delegation of Responsibilities Log locally.
Consent to enter this study will be obtained after a full account has been provided of its nature, purpose, risks, burdens and potential benefits, and the participant has had the opportunity to deliberate. The participant will be allowed to specify the time they wish to spend deliberating, usually up to 24 hours.
Periods shorter than 24 hours will be permitted if the participant feels that further deliberation will not lead to a change in their decision, and provided the person seeking consent is satisfied that the participant has fully retained, understood and deliberated on the information given.
Likewise, periods longer than 24 hours will be permitted should the participant request this. The Investigator or designee will explain that the participants are under no obligation to enter the study and that they can withdraw at any time during the study, without having to give a reason.
A copy of the signed Informed Consent Form (ICF), along with a copy of the most recent approved Participant Information Sheet (PIS) will be given to the study participant. The original signed consent form will be retained at the study site and filed in the Site Investigator File (ISF) / Trial Master File (TMF).
If new safety information results in significant changes to the risk-benefit assessment, the consent form and Participant Information Sheet will be reviewed and updated if necessary. All subjects, including those already enrolled, will be informed of the new information, given a copy of the revised consent form and PIS and asked to re-consent if they choose to continue in the study.
RANDOMISATION PROCEDURE A computer-generated program for random numbers will be used for simple randomization of participants https://www.randomizer.org/
This is a non-clinical randomised controlled trial of resident anaesthetists undergoing simulation training in regional anaesthesia. Residents will be randomised to one of two groups for each training session day:
DATA HANDLING AND ANALYSIS We will use RStudio to analyse data with appropriate packages. Examples include: Library (here, janitor, tidyverse, psych, dplyr, Hmisc, finalfit, ltm, lme4). Data will be stored on a University of Dundee managed laptop and OneDrive UoD database. Professor McLeod will be responsible for data analysis and storage. He will provide a report using Quatro.
Enrollment
Sex
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
102 participants in 2 patient groups
Loading...
Central trial contact
Boyne Bellew; Graeme MCLEOD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal